NCT01323959View on ClinicalTrials.gov

Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

March 1, 2012

Study Completion Date

March 1, 2012

Conditions
Acellular PertussisPoliomyelitisDiphtheriaTetanus
Interventions
BIOLOGICAL

BoostrixTM Polio

Single dose, intramuscular administration.

Trial Locations (15)

37000

GSK Investigational Site, Tours

37200

GSK Investigational Site, Tours

37250

GSK Investigational Site, La Riche

44277

GSK Investigational Site, Nantes

44300

GSK Investigational Site, Nantes

44450

GSK Investigational Site, La Chapelle-Basse-Mer

44590

GSK Investigational Site, Derval

80337

GSK Investigational Site, Munich

82362

GSK Investigational Site, Weilheim

85635

GSK Investigational Site, Höhenkirchen-Siegertsbrunn

93053

GSK Investigational Site, Regensburg

94469

GSK Investigational Site, Deggendorf

94474

GSK Investigational Site, Vilshofen

95152

GSK Investigational Site, Selbitz

97070

GSK Investigational Site, Würzburg

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY